Toggle Main Menu Toggle Search

Open Access padlockePrints

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

Lookup NU author(s): Dr Venetia BigleyORCiD



This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Society of Hematology, 2018.

For re-use rights please refer to the publisher's terms and conditions.


INTRODUCTION: The primary immunodeficiencies (PID), rare inherited diseases characterised by severe dysfunction of immunity have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in childhood. Controversy exists regarding optimal timing and use of Allo-HSCT in adults, due to lack of experience and previous poor outcomes. MATERIALS AND METHODS: 29 consecutive adult patients, with a mean age at transplant of 24 years (range 17-50) underwent Allo-HSCT. Reduced intensity conditioning included Flu/Mel/Alemtuzumab (n=20), Flu/Bu/Alemtuzumab (n=8) and Flu/Bu/ATG (n=1). Stem cell donors were matched or mismatched unrelated (MUD/MMUD) (n=18) and matched related donors (MRD) (n=11). Overall survival, event free survival, transplant related mortality, acute and chronic GVHD incidence and severity, time to engraftment, lineage specific chimerism, immune reconstitution and discontinuation of immunoglobulin replacement therapy were recorded. RESULTS: Overall survival (OS) at 3 years for the whole cohort was 85.2%. The rarer, non-CGD PID patients achieved an OS at 3 years of 88.9% (n=18), compared to 81.8% for CGD patients (n=11). Transplant related mortality (TRM) was low with only four deaths observed at a median follow-up of 3.5 years. There were no cases of early or late rejection. In all surviving patients either stable mixed chimerism or full donor chimerism were observed. At last follow-up 87% of the surviving patients had no evidence of persistent or recurrent infections. CONCLUSION: Allo-HSCT is safe and effective in young adult patients with severe PID and should be considered the treatment of choice where an appropriate donor is available.

Publication metadata

Author(s): Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding A, Peggs K, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, Dahlstrom J, Workman S, Symes A, Mackinnon S, Hough R, Morris E

Publication type: Article

Publication status: Published

Journal: Blood

Year: 2018

Volume: 131

Pages: 917-931

Print publication date: 22/02/2018

Online publication date: 26/12/2017

Acceptance date: 14/12/2017

Date deposited: 26/01/2018

ISSN (print): 0006-4971

ISSN (electronic): 1528-0020

Publisher: American Society of Hematology


DOI: 10.1182/blood-2017-09-807487

PubMed id: 29279357


Altmetrics provided by Altmetric